

1 **Title:** Protocol for a sequential, prospective meta-analysis to describe coronavirus disease  
2 2019 (COVID-19) in the pregnancy and postpartum periods

3  
4 Emily R. Smith<sup>1</sup>, Erin Oakley<sup>1</sup>, Siran He<sup>1</sup>, Rebecca Zavala<sup>1</sup>, Kacey Ferguson<sup>1</sup>, Lior Miller<sup>1</sup>, Gargi  
5 Wable Grandner<sup>1</sup>, Ibukun-Oluwa Omolade Abejirinde<sup>2</sup>, Yalda Afshar<sup>3</sup>, Homa Ahmadzia<sup>4</sup>, Grace  
6 Aldrovandi<sup>5</sup>, Victor Akelo<sup>6</sup>, Beth A. Tippet Barr<sup>6</sup>, Elisa Bevilacqua<sup>7</sup>, Justin S. Brandt<sup>8</sup>, Natalie  
7 Broutet<sup>2</sup>, Irene Fernández-Buhigas<sup>9, 10</sup>, Jorge Carrillo<sup>11</sup>, Rebecca Clifton<sup>12</sup>, Jeanne Conry<sup>13</sup>,  
8 Erich Cosmi<sup>14</sup>, Camille Delgado-López<sup>15</sup>, Hema Divakar<sup>16</sup>, Amanda J. Driscoll<sup>17</sup>, Guillaume  
9 Favre<sup>18</sup>, Valerie Flaherman<sup>19</sup>, Christopher Gale<sup>20</sup>, Maria M. Gil<sup>9, 10</sup>, Christine Godwin<sup>2, 21</sup>, Sami  
10 Gottlieb<sup>2</sup>, Olivia Hernandez Bellolio<sup>22</sup>, Edna Kara<sup>2</sup>, Sammy Khagayi<sup>23</sup>, Caron Rahn Kim<sup>2</sup>, Marian  
11 Knight<sup>24</sup>, Karen Kotloff<sup>17, 29</sup>, Antonio Lanzone<sup>25, 26</sup>, Kirsty Le Doare<sup>27, 28</sup>, Christoph Lees<sup>29</sup>, Ethan  
12 Litman<sup>4</sup>, Erica M. Lokken<sup>30, 31</sup>, Valentina Laurita Longo<sup>26</sup>, Laura A. Magee<sup>32, 33</sup>, Raigam Jafet  
13 Martinez-Portilla<sup>34, 35</sup>, Elizabeth McClure<sup>36</sup>, Torri D. Metz<sup>37</sup>, Deborah Money<sup>38</sup>, Edward Mullins<sup>29</sup>,  
14 Jean B. Nachega<sup>39, 40, 41</sup>, Alice Panchaud<sup>42, 43</sup>, Rebecca Playle<sup>44</sup>, Liona C. Poon<sup>45</sup>, Daniel  
15 Raiten<sup>46</sup>, Lesley Regan<sup>47</sup>, Gordon Rukundo<sup>48</sup>, Jose Sanin-Blair<sup>49</sup>, Marleen Temmerman<sup>50</sup>, Anna  
16 Thorson<sup>2</sup>, Soe Soe Thwin<sup>2</sup>, Jorge E. Tolosa<sup>49, 51, 52</sup>, Julia Townson<sup>44</sup>, Miguel Valencia-Prado<sup>53</sup>,  
17 Silvia Visentin<sup>14</sup>, Peter von Dadelszen<sup>32, 54</sup>, Kristina Adams Waldorf<sup>30, 31</sup>, Clare Whitehead<sup>55</sup>,  
18 Huixia Yang<sup>56</sup>, Kristian Thorlund<sup>57</sup>, and James M. Tielsch<sup>1</sup>

19  
20 1 Department of Global Health, George Washington University Milken Institute School of  
21 Public Health, Washington, DC, USA

22 2 Department of Sexual and Reproductive Health and Research, World Health Organization,  
23 Geneva, Switzerland

- 24 3 Division of Maternal Fetal Medicine, University of California Los Angeles, Los Angeles, CA,  
25 United States
- 26 4 Division of Maternal-Fetal Medicine, The George Washington University School of Medicine  
27 and Health Sciences
- 28 5 Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA
- 29 6 US Centers for Disease Control and Prevention, Kisumu, Kenya
- 30 7 Department of Women and Child Health, Women Health Area, Fondazione Policlinico  
31 Universitario Agostino Gemelli, IRCCS, Rome, Italy
- 32 8 Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and  
33 Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick,  
34 NJ, USA
- 35 9 Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de  
36 Ardoz, Madrid, Spain.
- 37 10 School of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain
- 38 11 Departamento de Obstetricia y Ginecología, Clínica Alemana de Santiago, Facultad de  
39 Medicina Clínica Alemana-Universidad del Desarrollo, Santiago, Chile
- 40 12 Biostatistics Center, The George Washington University, Washington, DC, USA
- 41 13 OBGYN, The International Federation of Gynecology and Obstetrics, London, United  
42 Kingdom
- 43 14 Department of Woman's and Child's Health, Obstetrics and Gynecologic Clinic, University of  
44 Padua, Padua, Italy

- 45 15 Surveillance for Emerging Threats to Mothers and Babies, Puerto Rico Department of  
46 Health, San Juan, Puerto Rico
- 47 16 Asian Research and Training Institute for Skill Transfer (ARTIST), Bengaluru, India
- 48 17 Center for Vaccine Development and Global Health, University of Maryland, School of  
49 Medicine, Baltimore, MD, USA
- 50 18 Materno-fetal and Obstetrics Research Unit, Department “Femme-Mère-Enfant”, University  
51 Hospital, Lausanne, Switzerland
- 52 19 Department of Pediatrics, University of California San Francisco, CA, San Francisco, USA
- 53 20 Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London,  
54 United Kingdom
- 55 21 Global Health Research, FHI 360, Durham, NC, USA
- 56 22 Gynecology and Obstetrics, Felix Bulnes Hospital and RedSalud Clinic, Santiago, Chile
- 57 23 Kenya Medical Research Institute-Center for Global Health Research, Kisumu Kenya
- 58 24 National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University  
59 of Oxford, Oxford, United Kingdom
- 60 25 Department of Women and Child Health, Women Health Area, Fondazione Policlinico  
61 Universitario Agostino Gemelli, IRCCS, Rome, Italy
- 62 26 Catholic University of Sacred Hearth, Rome, Italy
- 63 27 Medical Research Council /Uganda Virus Research Institute and London School of Hygiene  
64 & Tropical Medicine Uganda Research Unit, Entebbe, Uganda
- 65 28 Pediatric Infectious Diseases Research Group, St. George's University of London, United  
66 Kingdom

- 67 29 Department of Metabolism, Digestion, and Reproduction, Imperial College London, United  
68 Kingdom
- 69 30 Department of Obstetrics and Gynecology, School of Medicine, University of Washington,  
70 USA
- 71 31 Department of Global Health, School of Public Health, University of Washington,  
72 Washington, USA
- 73 32 Department of Women and Children's Health, School of Life Course Sciences, King's  
74 College London, United Kingdom
- 75 33 Institute of Women and Children's Health, King's College Hospital, London, UK
- 76 34 Clinical Research Division, National Institute of Perinatology, Mexico City, Mexico
- 77 35 ABC Medical Center, Fetal Surgery Clinic, Mexico City, Mexico
- 78 36 Division of Statistics and Epidemiology, RTI International, NC, USA
- 79 37 University of Utah Health, USA
- 80 38 Department of Obstetrics and Gynecology, The University of British Columbia, Vancouver,  
81 Canada
- 82 39 Department of Epidemiology and Center for Global Health, University of Pittsburgh  
83 Graduate School of Public Health, Pittsburgh, PA, USA
- 84 40 Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University,  
85 Cape Town, South Africa
- 86 41 Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of  
87 Public Health, Baltimore, MD, USA
- 88 42 Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

- 89 43 Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne  
90 Switzerland
- 91 44 Center for Trials Research, Cardiff University, Wales, United Kingdom
- 92 45 Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong  
93 Kong
- 94 46 Pediatric Growth and Nutrition Branch, National Institute of Health, Bethesda, MD, USA
- 95 47 Federation International Federation Gynaecology & Obstetrics, Imperial College London  
96 United Kingdom
- 97 48 PeriCovid (PREPARE) – Uganda Team, Makerere University – Johns Hopkins University  
98 Research Collaboration, Uganda
- 99 49 Maternal Fetal Unit. Universidad Pontificia Bolivariana. RECOGEST Study. Colombia.
- 100 50 Department of Obstetrics and Gynecology, Aga Khan University, Nairobi, Kenya
- 101 51 Department of Obstetrics and Gynecology, Maternal Fetal Medicine, Oregon Health and  
102 Science University, Portland, OR, USA
- 103 52 St. Luke's University Health Network, Department of Obstetrics & Gynecology, Maternal  
104 Fetal Medicine, Bethlehem, PA, USA
- 105 53 Children with Special Medical Needs Division, Puerto Rico Department of Health, San Juan,  
106 Puerto Rico
- 107 54 Global Health Institute, King's College London, United Kingdom
- 108 55 Department of Maternal Fetal Medicine, University of Melbourne, Royal Women's Hospital,  
109 Parkville, VIC, Australia
- 110 56 Health Science Center, Peking University, Beijing, China

111 57 Department of Health Research Methods Evidence and Impact, McMaster University,

112 Hamilton, ON, Canada

113

114

115 **\*Corresponding Author:**

116 Email: [EmilySmith@gwu.edu](mailto:EmilySmith@gwu.edu) (ES)

117

118

## 119 **Abstract**

120           We urgently need answers to basic epidemiological questions regarding SARS-CoV-2  
121 infection in pregnant and postpartum women and its effect on their newborns. While many  
122 national registries, health facilities, and research groups are collecting relevant data, we need a  
123 collaborative and methodologically rigorous approach to better combine these data and address  
124 knowledge gaps, especially those related to rare outcomes. We propose that using a sequential,  
125 prospective meta-analysis (PMA) is the best approach to generate data for policy- and practice-  
126 oriented guidelines. As the pandemic evolves, additional studies identified retrospectively by the  
127 steering committee or through living systematic reviews will be invited to participate in this PMA.  
128 Investigators can contribute to the PMA by either submitting individual patient data or running  
129 standardized code to generate aggregate data estimates. For the primary analysis, we will pool  
130 data using two-stage meta-analysis methods. The meta-analyses will be updated as additional  
131 data accrue in each contributing study and as additional studies meet study-specific time or data  
132 accrual thresholds for sharing. At the time of publication, investigators of 25 studies, including  
133 more than 76,000 pregnancies, in 41 countries had agreed to share data for this analysis.  
134 Among the included studies, 12 have a contemporaneous comparison group of pregnancies  
135 without COVID-19, and four studies include a comparison group of non-pregnant women of  
136 reproductive age with COVID-19. Protocols and updates will be maintained publicly. Results will  
137 be shared with key stakeholders, including the World Health Organization (WHO) Maternal,  
138 Newborn, Child, and Adolescent Health (MNCAH) Research Working Group. Data contributors  
139 will share results with local stakeholders. Scientific publications will be published in open-access  
140 journals on an ongoing basis.

141

142

## 143 Introduction

144 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to over 244  
145 million confirmed cases of coronavirus disease 2019 (COVID-19) and claimed more than 4.9  
146 million lives globally, as of October 2021 [1], and these are likely underestimates [2]. The World  
147 Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC)  
148 note that pregnant women may be at higher risk of developing severe illness due to COVID-19  
149 [3,4]. The specific mechanisms for this increased risk are unknown, though may be related to  
150 physiologic and immunologic changes during pregnancy. Pregnant women are generally at  
151 increased risk for severe illness from many infectious diseases including influenza, hepatitis E,  
152 malaria, and herpes simplex virus [5]. Additionally, other coronaviruses such as severe acute  
153 respiratory syndrome (SARS) are thought to pose higher risks for adverse outcomes to  
154 pregnant people; although there is only a single case-control study comparing 10 pregnant to 40  
155 non-pregnant SARS patients [6,7].

156 Pregnant women with COVID-19, and their offspring, may be at increased risk for  
157 complications due to severe illness and adverse pregnancy outcomes. A living systematic  
158 review suggests that pregnant women with COVID-19, compared to non-pregnant women with  
159 COVID-19, are more than twice as likely to be admitted to an intensive care unit (ICU) or require  
160 invasive ventilation [8]. In an observational cohort study of 1,219 pregnant women across 33  
161 U.S. hospitals with positive SARS-CoV-2 test (molecular or antigen) at the time of delivery,  
162 severe or critical COVID-19 was associated with a 40% increase in hypertensive disorders of  
163 pregnancy and a 42% increase in preterm birth, as compared to asymptomatic pregnant  
164 patients [9]. A multi-national case-control study (INTERCOVID) including 706 pregnant women  
165 with COVID-19 and 1,424 pregnant women without COVID-19 found that COVID-19 diagnosis  
166 was associated with increased risk of preeclampsia and eclampsia, severe infections, intensive  
167 care unit (ICU) admission and death [10]. A pooled analysis of 41 studies including 3323



168 pregnant women with COVID-19 found that one-third of their newborns were admitted to the  
169 neonatal intensive care unit (NICU); a meta-analysis of ten studies found that newborns born to  
170 pregnant women with COVID-19 were nearly five times more likely to be admitted to the NICU  
171 as compared to COVID-19 negative pregnancies [8]. Reports of mother-to-child transmission of  
172 SARS-CoV-2 during the antepartum, intrapartum, or early postnatal period remain limited.

173         Despite the urgent need to accurately document the number of cases, severe illness,  
174 and deaths in pregnant women, available data on maternal and infant complications related to  
175 COVID-19 remain heterogenous [11]. The high degree of heterogeneity in study designs,  
176 comparison groups, and definitions of key health outcomes across studies makes it difficult to  
177 clearly understand any excess risks and guide policy for pregnant and postpartum women and  
178 their newborns. For example, the current (February 2021) living systematic review on COVID-19  
179 in pregnancy included 192 studies with 64,676 pregnant and postpartum patients; the  
180 heterogeneity in published outcomes meant that only a small fraction of those studies could be  
181 combined for key analyses, and data from some regions of the world, (e.g., sub-Saharan Africa)  
182 were absent. For example, data were available from only a handful of studies to examine a few  
183 risk factors for a single outcome (severe COVID and death), and there were fewer than 10  
184 studies that compared the risk of maternal, fetal, and newborn outcomes between pregnant and  
185 postpartum patients versus either pregnant patients without COVID-19 or nonpregnant women  
186 of reproductive age with COVID-19 [8]. Further, we have limited data on the efficacy of  
187 treatments and preventives in pregnancy and postpartum, due largely to the systematic  
188 exclusions of pregnant people from the relevant clinical trials until recently. The same was true  
189 of the seminal vaccine trials, although vaccine studies among pregnant women began in early  
190 2021 (ClinicalTrials.gov Identifier: NCT04754594) [12]. Establishing mother-to-child  
191 transmission of SARS-CoV-2 has also been challenging because consensus was lacking on  
192 case definition for intrauterine, intrapartum or early postpartum transmission of SARS-CoV-2

193 until February 2021 [13], and all proposed definitions have required clinicians and researchers  
194 to follow specific testing protocols [14–18].

195 COVID-19 data in pregnancy and infancy was scarce at first, and now it is  
196 heterogeneous. These shortcomings exist in part because data collection protocols have  
197 differed, and the underlying population risks for severe illnesses vary globally. It is therefore  
198 necessary to generate high-quality information with a unified data harmonization plan and  
199 analytic strategy. This approach will permit us to make evidence-driven decisions and to create  
200 guidelines for the prevention and treatment of COVID-19 in pregnant women. Because little of  
201 the existing data can be pooled, our ability to make strong recommendations related to COVID-  
202 19's risks in pregnancy and the postpartum period is limited. We are similarly constrained in our  
203 capacity to offer guidance as to the potential benefits of new interventions, like vaccines. So we  
204 propose to fill this gap by conducting a sequential prospective meta-analysis (PMA). This PMA  
205 will be a robust, collaborative, global approach to accrue harmonized data, with the objective of  
206 generating policy and practice-relevant data about the epidemiology of COVID-19 in the  
207 pregnancy and postnatal periods.

208

209

## 210 **Methods**

211 The protocol for this serial prospective meta-analysis was registered with PROSPERO  
212 (ID: 188955) on May 28, 2020. A prospective meta-analysis identifies studies that will contribute  
213 data to the meta-analysis, as well as establishes the analysis plans, before the results of the  
214 individual studies are known [19]. This approach is similar to a multi-site registry or cohort in the  
215 sense that studies work to harmonize collection of key outcomes, but differs from multi-site  
216 studies in that each site implements a study design and local protocol that is appropriate for

217 their context [19]. Our goal is to provide a maximally flexible, robust, collaborative, and inclusive  
218 analysis framework that is methodologically appropriate.

219

## 220 **Ethical Approval**

221 All individual study sites will obtain appropriate ethical approval for their independent  
222 data collection activities. As this project is a meta-analysis using aggregate study estimates or  
223 analyses of secondary, de-identified individual patient data, it is not classified as human  
224 research and thus is exempt from IRB approval.

225

## 226 **Language**

227 Not all those who are pregnant or give birth identify as women. We use the terms  
228 “pregnant women” and “pregnant people” throughout. This accurately reflects both study  
229 designs (e.g. a comparison group including those who self-report as women between the ages  
230 to 15 and 45) and the language used by the studies contributing data.

231

## 232 **Research Questions**

233 The study aims to answer basic epidemiological questions about COVID-19 and its  
234 impact on maternal and newborn health by pooling data from independent studies using  
235 harmonized data definitions and an individual patient data meta-analytic framework to minimize  
236 data variability.

237

238 Analyses will be performed in three groups. First, we will provide descriptive statistics among  
239 pregnant women with COVID-19. To understand the relative risks associated with COVID-19 in  
240 pregnancy, we will compare pregnant people with COVID-19 to i) other pregnant people without  
241 COVID-19 and ii) non-pregnant women of reproductive age (15-45 years) with confirmed or  
242 suspected COVID-19.

243 Specific objectives regarding COVID-19 among pregnant or postpartum women include:  
244 i) describe the natural history of COVID-19; ii) estimate the incidence of and risk factors for  
245 hospitalization, admission to intensive care unit, receipt of critical care, and use of invasive  
246 ventilation (for COVID-19); and iii) estimate the infection and case fatality rate. For each of  
247 these outcomes, we will also compare the risk for pregnant women with COVID-19 to non-  
248 pregnant women of reproductive age with confirmed or suspected COVID-19.

249 Specific objectives regarding maternal health among pregnant or postpartum women  
250 with COVID-19 are to estimate the incidence or prevalence of: i) maternal morbidities including  
251 hypertensive disorders of pregnancy, abnormal placentation, preterm prelabor rupture of  
252 membranes, hemorrhage, embolic disease, etc. ; ii) maternal and pregnancy-related death; iii)  
253 adverse pregnancy outcomes including stillbirth, preterm birth, small-for-gestational age birth,  
254 and low birthweight. For each of these outcomes, we will also compare the risk for pregnant  
255 women with COVID-19 to other pregnant women without COVID-19.

256 Specific objectives regarding newborn health among newborns born to patients with  
257 COVID-19 are to estimate the incidence and timing of and risk factors for: i) congenital  
258 anomalies; ii) perinatal and (early) neonatal mortality; and iii) intrauterine, intrapartum, or early  
259 peripartum transmission of SARS-CoV-2 from mother to child. When appropriate, we will  
260 compare these risks to those of newborns born to women without COVID-19 during pregnancy.

261 Specific objectives regarding SARS-CoV-2 in biospecimens (e.g. nasopharyngeal,  
262 vaginal, or rectal swab, maternal blood, pregnancy tissue, placenta, amniotic fluid, cord blood,  
263 breast milk) include estimating: i) the proportion of biospecimens with detectable SARS-CoV-2  
264 virus and median viral load; ii) the association between virus or viral load in biospecimen and  
265 key outcomes described above.

266

## 267 **Search strategy & study inclusion**

268 We originally recruited study sites to join the proposed prospective meta-analysis first via  
269 professional research networks, and subsequently via key stakeholder networks. Stakeholders  
270 at the National Institute of Child Health and Human Development (NICHD) at the U.S. National  
271 Institutes of Health (NIH) supported recruitment of NIH-funded maternal and child health  
272 network groups and other U.S. government funded projects. Stakeholders at the World Health  
273 Organization (WHO) in the Departments of Maternal, Newborn, Child, and Adolescent Health  
274 (MNCAH) and of Sexual and Reproductive Health and Research (SRH) supported recruitment  
275 of researchers engaged in the COVID-19 MNCAH research network and the SRH pregnancy  
276 cohorts working group [20]. Stakeholders from the International Federation of Gynecology and  
277 Obstetrics (FIGO) supported recruitment by issuing an invitation through their international  
278 network. Studies were invited to participate based solely on study design. Eligible study designs  
279 included: i) registries enrolling all suspected or confirmed cases in pregnancy or postpartum  
280 period, ii) cohorts enrolling all pregnant women, or iii) case-control studies enrolling pregnant or  
281 postpartum women with suspected or confirmed COVID-19. There were no *a priori* sample size  
282 limitations due to the dynamic epidemiology of the pandemic. Study investigators confirmed  
283 their intent to contribute to the PMA via a letter of intent or signing a collaboration agreement.

284

285 Building on concepts laid out in the Framework for Adaptive Meta-analyses (FAME) [21],  
286 we will also collaborate with the PregCOV-19 Living Systematic Review Consortium to identify  
287 studies that might be eligible for post-publication inclusion into the proposed meta-analysis. The  
288 search strategy for the LSR was previously published [8,22]. We will screen all published  
289 studies included in the living systematic review for potential inclusion in the PMA using the  
290 following criteria: i) the study conforms to the study designs outlined above; ii) there is a defined  
291 catchment area (e.g., certain hospitals, states, etc.); and iii) the sample size included at least 25  
292 pregnant or postpartum people with confirmed or suspected COVID-19 who were consecutively  
293 recruited or identified through surveillance.

294

## 295 **Exposure (Suspected or Confirmed SARS-CoV-2 Infection)**

296 Confirmed cases of COVID-19 will be defined as those with laboratory-confirmed SARS-  
297 CoV-2 infection via a nucleic acid amplification test, regardless of clinical signs or symptoms.  
298 The original protocol was expanded to include COVID-19 cases confirmed via antigen tests as  
299 they became validated and widely used over the course of the pandemic. Suspected cases will  
300 be defined according to the WHO August 7, 2020 case definition based on either a) clinical  
301 (acute onset fever and cough, or acute onset of three or more pre-identified signs and  
302 symptoms) and epidemiological criteria (residing, working, or traveling in an area with high risk  
303 of transmission or community transmission in the past 14 days or working in any health care  
304 setting) or the severe acute respiratory illness (SARI) case definition [23]. Probable COVID-19  
305 infections will also be defined according to the WHO August 7, 2020 case definition (clinical  
306 criteria and contact with a case; a suspected case with chest imaging, recent anosmia or  
307 ageusia onset without other cause, respiratory disease preceding death and contact with a  
308 case) [23].

309

## 310 **Outcomes of Interest**

311 Outcomes related to women's health will include:

- 312 ● Mortality: all-cause mortality, COVID-19 specific mortality, and pregnancy-related and  
313 maternal mortality;
- 314 ● COVID-19 related clinical signs and symptoms: fever, cough, shortness of breath,  
315 dizziness or fainting, body aches, runny nose, sore throat, loss of sense of smell, loss of  
316 sense of taste, sneezing, fatigue, nausea, vomiting, diarrhea, and headache;
- 317 ● Morbidity and healthcare utilization related to COVID-19 severity: pneumonia diagnosis,  
318 hospitalization, admittance to an intensive care unit (ICU), or use of critical care  
319 interventions;
- 320 ● Pregnancy-related morbidities: hypertensive disorders of pregnancy including  
321 gestational hypertension, preeclampsia, eclampsia, hyperemesis gravidarum, fetal  
322 growth restriction, abnormal placentation (placenta previa and placenta accreta  
323 spectrum), placental abruption, preterm labor, preterm prelabor rupture of membranes,  
324 hemorrhage (antepartum/intrapartum; postpartum; abortion-related), embolic disease, or  
325 anesthetic complications. We also collected data on cesarean delivery.
- 326 ● Adverse pregnancy outcomes: stillbirth (fetal death  $\geq 28$  weeks' gestation per WHO  
327 definition), early preterm birth (<34 weeks gestation), preterm birth (<37 weeks  
328 gestation), small-for-gestational-age birth (<3rd and <10th percentile per the  
329 INTERGROWTH-21<sup>st</sup> newborn reference values) [24], short-for-gestational-age birth  
330 (<3rd and <10th percentile per the INTERGROWTH-21<sup>st</sup> newborn reference values on  
331 length [25], low birthweight (<2500 grams), and very low birthweight (<1500 grams).
- 332 ● Presence of SARS-CoV-2 and viral load in maternal biological specimens including:  
333 amniotic fluid, placenta (maternal or fetal side), cord blood, vaginal swab, feces or rectal

334 swab, nasopharyngeal swab, pregnancy tissue (fetus or pregnancy sac and placenta) in  
335 the case of stillbirth or abortion, breastmilk, and maternal blood.

336

337 Neonatal outcomes of interest include:

- 338 • Congenital anomalies: neural tube defects, microcephaly, congenital malformations of  
339 ear, congenital heart defects, orofacial clefts, congenital malformations of digestive  
340 system, congenital malformations of genital organs, abdominal wall defects,  
341 chromosomal abnormalities, reduction defects of upper and lower limbs, or talipes  
342 equinovarus (clubfoot);
- 343 • Early neonatal ( $\leq 7$  days) and neonatal ( $\leq 28$  days) death;
- 344 • Perinatal death (stillbirth ( $\geq 28$  weeks) or early neonatal death ( $\leq 7$  days));
- 345 • Admission to and length of stay in neonatal intensive care unit (NICU);
- 346 • Mother-to-child transmission of SARS-CoV-2 (differentiating intrauterine versus  
347 intrapartum or early peripartum infection if possible).

348

## 349 **Data Harmonization**

350 We developed the draft data modules and questions in April 2020 based on a proposed  
351 set of questions from the Pregnancy CoRonavirus Outcomes RegIsTrY (PRIORITY) study  
352 (ClinicalTrials.gov Identifier: NCT04323839). We also reviewed and included questions from the  
353 case report and data collection forms developed by the Department of Sexual and Reproductive  
354 Health (SRH), HRP, WHO and the WHE, WHO prospective cohort study, and the U.S. Centers  
355 for Disease Control and Prevention (CDC) Surveillance for Emerging Threats to Mothers and  
356 Babies Network (SET-NET) study [26,27]. We requested two rounds of feedback via a survey  
357 and by email from the >50 participants of the bi-monthly informal meeting established at the



358 beginning of the pandemic called the “Perinatal COVID-19 Global Gathering”. The current data  
359 modules reflect feedback and general consensus among survey respondents. The final draft of  
360 the data modules and core variables was finalized and shared broadly on June 2, 2020 (S File  
361 1). We updated the data modules in September 2020 to reflect evolving understanding of  
362 SARS-CoV-2 infection in newborns and to reflect the updated SRH, HRP, WHE UNITY generic  
363 protocol developed by WHO for COVID-19-related pregnancy cohort studies [26] (S File 2).

364

## 365 **Data Sharing & Study-Specific Data Analysis**

366 We will develop a codebook and statistical codes for each contributing study to map  
367 original study variables to the PMA core variables. Investigators can join the PMA either by  
368 submitting individual patient data or running standardized code to generate aggregate data  
369 estimates that can be included in the meta-analysis. The same data quality and consistency  
370 checks will be performed for each study, and any issues will be resolved with study  
371 investigators. Studies will be eligible to contribute data to the PMA when they have accrued at  
372 least 25 confirmed cases with completed follow up.

373 Study-specific estimates for the two-stage meta-analysis will be produced using  
374 standardized analytical codes, and aggregated measures will be exported into a database for  
375 the meta-analyses. Individual studies are expected to proceed with their own study publications  
376 and can use any analyses generated by the PMA for publication or policy making in their study  
377 context.

378

## 379 **Overlapping Data**

380 For each updated meta-analysis, we will review included studies for potentially  
381 overlapping participants to avoid including individual participants in the estimates for more than  
382 one study. We will choose a single study to contribute cases from given locations (e.g. health  
383 facilities, cities, states, or countries). The study with the most complete data will be selected to  
384 contribute, or in the case of similar data between studies, we will include data from the study  
385 that was the first to join the PMA. The number of studies and the number of cases per study is  
386 therefore likely to change with each updated meta-analysis, given this robust analytical strategy.  
387 We will use a modified version of the Newcastle Ottawa Scale to assess the risk of bias of  
388 individual studies.

389

## 390 **Methods for Data Synthesis**

391 Ideally, all individual-level data would be combined for one-stage meta-analysis.  
392 However, we anticipate that the ability to quickly share data and the degree of willingness to  
393 share individual patient data may vary by country and across collaborators and institutions.  
394 Thus, we will plan for a step-wise statistical analysis plan where the most feasible and simple  
395 analyses (that contribute directly to our research questions) are prioritized, and more advanced  
396 statistical modelling will be conducted subsequently.

397 For the first stage of analysis, prevalence, and incidence data for the respective  
398 outcomes, overall and by risk factor, will be pooled using the conventional DerSimonian-Laird  
399 random-effects model [28]. For analyses where only proportions or crude incidence rates are  
400 used, the Arcsine method may be applied to stabilize the statistics and ensure approximate  
401 asymptotic normality [29]. For analyses comparing pregnant COVID-19 cases to a) COVID-19  
402 negative pregnancies or b) non-pregnant women with COVID, we will calculate the relative risk  
403 or odds ratio (for case-control studies) for each outcome; effect estimates will be pooled using

404 the conventional DerSimonian-Laird random-effects model [28]. We will assess forest plots  
405 visually for heterogeneity. When at least ten studies are being pooled, we will also quantify  
406 heterogeneity by the  $I^2$  statistic [30].

407

## 408 **Analysis of Subgroups**

409 Where appropriate and as sample size allows, we will consider meta-regression or  
410 subgroup analyses by the following study level characteristics: study design and sampling  
411 strategy, proportion of confirmed COVID-19 cases (out of suspected and confirmed cases),  
412 national maternal mortality ratio, national neonatal mortality rate, and geographic region. We will  
413 also consider subgroup analysis by the following individual patient characteristics to identify risk  
414 factors or effect modifiers for specific outcomes: confirmed versus suspected COVID-19 case  
415 status; gestational age at COVID-19 onset (by week or by trimester), COVID-19 severity, pre-  
416 pregnancy health conditions or comorbidities [diabetes, hypertension, cardiovascular disease,  
417 obesity (Body Mass Index  $\geq 30$  kg/m<sup>2</sup>), underweight (Body Mass Index  $< 18.5$  kg/m<sup>2</sup>),  
418 tuberculosis, malaria, HIV/AIDS, syphilis, anemia (hemoglobin  $< 11$  g/dL)], maternal morbidities  
419 (also described above as outcomes), maternal vaccination status (influenza, COVID-19),  
420 calendar time or time since first COVID-19 diagnosis in the study area, parity, maternal age,  
421 race or ethnicity, and maternal education. Some of these risk factors may be considered both  
422 outcomes of having COVID-19 in pregnancy or factors that exacerbate SARS-CoV-2 infection in  
423 pregnancy; we will attempt to disambiguate between the two based on the timing of diagnoses  
424 whenever possible.

425

## 426 **Sample size considerations**

427 Consistent with the GRADE event-based approach, we will avoid “very low precision” by  
428 requiring a minimum number of three sites or a total of 100 events for each outcome to run the  
429 first analysis [31]. As data accumulate, we will evaluate the robustness of the inferences and  
430 whether the answer can be reasonably inferred via a conservative sample size. Assuming at  
431 least 50% heterogeneity between sites, the need for 90% power and 5% type 1 error to detect a  
432 difference, a conservative 1% prevalence/incidence and a risk ratio of 1.5 for the considered  
433 subgroup, a minimum of 30,000 participants are required to demonstrate an effect for each  
434 outcome and the proposed subgroups (risk factors). Alternatively, a total of 400 events or more  
435 may be used as a threshold for ‘sufficient evidence’ in accordance with recommendation of the  
436 GRADEPROfiler [31,32]. When these thresholds are met, the steering committee must decide  
437 whether additional, updated meta-analyses will be performed.

438

## 439 **Governance**

440 The steering committee will consist of at least one member from each participating site,  
441 key stakeholders (S File 3), and the technical coordinating team at the George Washington  
442 University. When a formal vote is needed, the following teams will each cast one official vote:  
443 each group of investigators linked to participating studies, each key stakeholder organization,  
444 and the technical coordinating team. The steering committee will prioritize research questions  
445 and agree on common elements of data collection. They will disseminate results, including rapid  
446 reports to key stakeholders, webinars, and submission of manuscripts to preprint servers and  
447 scientific journals. The technical coordinating team will develop protocols for data transfer and  
448 ensure data quality; write the statistical analysis plans; and conduct meta-analyses.

449

450

## 451 **Participating studies**

452           At the time of publication, 25 studies (in 41 countries) were actively participating in the  
453 ongoing PMA (Table 1). Among these studies, 11 have a contemporaneous comparison group  
454 of pregnancies without COVID-19; two studies include a comparison group of non-pregnant  
455 women of reproductive age. The median anticipated sample size of participating studies is  
456 1,500.           More           than           76,000           pregnancies

457 in total are expected to contribute to the completed meta-analyses (Table 1). These studies  
458 include data from 41 countries: Argentina, Australia, Bangladesh, Belgium, Brazil, Canada,  
459 Chile, China, Colombia, Democratic Republic of the Congo, Egypt, France, French Guyana, The  
460 Gambia, Germany, Ghana, Guatemala, Hong Kong, India, Israel, Italy, Kenya, Lebanon, Mali,  
461 Mexico, Mozambique, Netherlands, New Zealand, Nigeria, Pakistan, Peru, Portugal, Puerto  
462 Rico, Rwanda, South Africa, Spain, Sweden, Switzerland, Turkey, Uganda, United Kingdom,  
463 United States, and Zambia (Fig 1). Data from additional countries is expected from the WHO  
464 prospective cohort study and other studies that will be identified via the published literature. A  
465 description of each study, including the study investigators and institutional affiliations, study  
466 design description, recruitment methods, anticipated sample sizes, recruitment timeline, and  
467 primary outcomes are presented in supplementary tables (S3 File).

468 **Table 1. Characteristics of participating studies**

Study	Country of Study	Anticipated Sample Size (Pregnant Women)	Pregnant COVID-19 Case Recruitment Strategies					Comparison Group		
			Universal COVID-19 Screening		COVID-19 Care					
			Labor & Delivery	Antenatal Care	Hospitalized for COVID	Outpatient Care for COVID-19	Testing Site (Symptoms or Exposure)	None	Non-COVID-19 Pregnancies	Non-pregnant COVID-19 cases
AFREHealth	Multiple <sup>1</sup>	350			X				X	X
ANCOV Kenya	Kenya	2500	X	X		X	X		X	
ARTIST India	India	300	X	X			X	X		
CanCOVID-Preg	Canada	6000	Mixed		X	X	X		X	X
Cerner Real World Data	USA	5000	Mixed						X	
China/Hong Kong	China, Hong Kong	146	X		X		X	X		
CHOPAN Australia	Australia, Zealand	New 50							X	
COVI-Preg	Multiple <sup>2</sup>	1700	X		X	X	X		X	
Gestacovid Chile	Chile	1500	X	X	X	X	X	X		
Madrid Registry	Spain	200	X	X			X	X		
Mali ANC + Surveillance	Mali	3000		X		X	X		X	
Mali ANC Case-Control	Mali	1500		X					X	
Mexico National Registry	Mexico	11031	X		X					X
NICHD Global Network	Multiple <sup>3</sup>	20,000	Random Sample						X	
NICHD MFMU Network	United States	14,000	Most	X	X	X	X		X	
PANCOVID	Multiple <sup>4</sup>	8263	X		X	X		X		
PERICOVID (PRECISE)	Multiple <sup>5</sup>	6000		X					X	X
PERICOVID (PREPARE)	Multiple <sup>6</sup>	400	X	X	X	X	X		X	

PRIORITY USA	United States	1500	X	X	X	X	X	X
Puerto Rico CASSS	Puerto Rico	458	X			X	X	X
RECOGEST Colombia	Colombia	500			X		X	X
Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome	Italy	230	X		X	X		X
UKOSS	United Kingdom	7000	X		X		X	X
Washington State COVID-19 in Pregnancy Collaborative	USA	240	X <sup>7</sup>		X	X	X	X
WHO Prospective Cohorts	Multiple <sup>8</sup>	>16,000	X	X	X	X	X	X

469 1 Democratic Republic of the Congo, Ghana, Kenya, Nigeria, South Africa, and Uganda

470 2 USA, Canada, Mexico, Colombia, French Guyana, Peru, Brazil, Argentina, Chile, Australia, Rwanda, Lebanon, Israel, China, Portugal, Spain, France, Italy,  
 471 United Kingdom, Switzerland, Germany, Belgium, Netherlands, Ireland, and Egypt

472 3 India, Pakistan, Bangladesh, Kenya, DRC, Zambia, and Guatemala

473 4 United Kingdom, Albania, Argentina, Austria, Chile, China, Czech Republic, Egypt, Greece, Hong Kong, Indonesia, India, Italy

474 5 The Gambia, Mozambique, and Kenya

475 6 Uganda, Malawi

476 7 Universal testing prior to labor & delivery admission was not uniform across all participating clinical sites, but occurred in the majority by May of 2020. The  
 477 remaining hospitals initiated universal testing for scheduled delivery admissions only.

478 8 The generic protocol for the WHO prospective cohort study is available for countries at: <https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2>. The final list of participating countries that will  
 479 contribute to the meta-analysis is being confirmed.  
 480

481

482 **Fig 1. Map of participating study sites**

483



## 484 Discussion

485 Our sequential, prospective meta-analysis aims to pool individual patient data from  
486 ongoing or completed studies, registries, and surveillance programs that identify SARS-CoV-2  
487 infections in pregnancy and postpartum.

488 There are several benefits to our approach, which is guided by the principles of flexibility,  
489 robustness, collaboration, and inclusion. Early efforts to plan for pooling can reduce research  
490 waste (e.g., incompatible data, duplication of efforts) and improve the collective value of data  
491 [33]. Through collaboration since April 2020, including participation in WHO-coordinated working  
492 groups, we have developed and shared data collection tools and standardized some data  
493 collection components while several participating studies were starting their respective  
494 research. Ongoing pooling has also highlighted where data elements are missing or sparse  
495 across studies, thus providing justification for additional effort from study investigators to  
496 retrospectively extract additional data or modify their data collection forms. Further, this  
497 collaborative approach of pooling data highlights the possibility of generating robust answers to  
498 questions of collective importance at a global scale [34,35]. We are also more likely to elucidate  
499 risks related to rare outcomes. Collaboration is especially important for achieving scientific  
500 consensus regarding special populations—such as pregnant patients and newborns—who may  
501 not be specifically considered in national surveillance programs and may be actively excluded  
502 from other clinical research.

503 Our approach uses statistical methods for individual patient data meta-analysis, which is  
504 generally considered to be the gold standard in pooling data given the many steps used to  
505 ensure quality and consistency of the data and analyses. All data will be reviewed with the same  
506 data quality assessments, and outliers will be assessed consistently across studies. Analysis  
507 definitions will be standardized across studies. This is especially important given that for many

508 outcomes, study definitions vary between countries (e.g. whether a woman should receive  
509 critical care, the gestational age cutoff for defining stillbirth). Furthermore, we will avoid duplicate  
510 case counting by working with and reanalyzing data from studies that include overlapping health  
511 facilities and centers that contribute to two or more studies. This has been a major issue in  
512 COVID-19-related meta-analyses because much scientific literature is based on case reports or  
513 case series; the same cases sometimes appear in multiple published papers. Traditional meta-  
514 analyses based on the published literature cannot resolve these methodological issues.

515         Importantly, this approach is robust, flexible and collaborative. Each set of investigators  
516 can implement their own protocol, offering more flexibility to design a study specific to a given  
517 setting. Investigators can also proceed with their own study publications, thus ensuring an  
518 opportunity to be explicit about the local context in which the data collection took place and  
519 clearly take the credit associated with authorship. Our basic analyses will be done as a two-  
520 stage meta-analysis, allowing us flexibility in how data is shared. Studies that are willing and  
521 able can share their individual patient data directly with the data coordinating team for central  
522 analysis. Alternatively, studies that are unwilling or unable to share individual patient data can  
523 appoint their own study-specific data analyst to join the PMA data coordinating team. This  
524 approach to a “distributed” individual patient data meta-analysis meets data sharing needs for  
525 different groups, and hopefully ensures that anyone can participate. Finally, our regular steering  
526 committee meeting allows for joint decision-making about which analyses should be prioritized  
527 and when to move forward with publications. We hope to be responsive to emerging, policy-  
528 relevant questions, such as the safety and efficacy of vaccination in pregnancy.

529

530

## 531 **Conclusion**

532           Prospective meta-analyses offer a rigorous way to generate definitive answers to  
533 emerging questions. In the current context of the COVID-19 pandemic, there is limited high-  
534 quality data that can be pooled in order to inform public health guidance and healthcare  
535 strategies, specifically for pregnant women and their newborns. The proposed study will  
536 contribute necessary information for evidence-based decision-making related to COVID-19 and  
537 maternal and neonatal health.

538

539

## 540 **Author Contributions**

541 ES, EO, SH, JMT were involved in the conceptualization and methodology; ES, EO were  
542 responsible for data curation; ES, VF, YA were responsible for funding acquisition; ES led  
543 investigation and writing the original draft manuscript; EO, SH contributed to the writing –  
544 original draft preparation; ES, EO conducted the analysis; EO, RZ contributed to visualization;  
545 ES, JMT provided supervision. EO, SH, RZ, KF, LM, and GWG contributed to project  
546 administration. All authors contributed to writing – review & editing.

547

548

## 549 **References**

- 550 1 Johns Hopkins University. COVID-19 map-Johns Hopkins Coronavirus Resource Center.  
551 2020.<https://coronavirus.jhu.edu/map.html>
- 552 2 The true death toll of COVID-19: estimating global excess mortality.  
553 <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess->

- 554 mortality (accessed 26 Jul 2021).
- 555 3 CDC. Coronavirus Disease 2019 (COVID-19). 2020.<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html> (accessed 16 Sep 2020).
- 556
- 557 4 (hq) WH. COVID-19 Clinical management: living guidance.  
558 2021.<https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1> (accessed 26  
559 Jul 2021).
- 560 5 Sappenfield E, Jamieson DJ, Kourtis AP. Pregnancy and susceptibility to infectious  
561 diseases. *Infect Dis Obstet Gynecol* 2013;**2013**:752852.
- 562 6 Lam CM, Wong SF, Leung TN, *et al*. A case-controlled study comparing clinical course and  
563 outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome.  
564 *BJOG* 2004;**111**:771–4.
- 565 7 Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from Coronavirus 2019-  
566 nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other  
567 Human Coronavirus Infections. *Viruses* 2020;**12**:194.
- 568 8 Allotey J, Stallings E, Bonet M, *et al*. Clinical manifestations, risk factors, and maternal and  
569 perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and  
570 meta-analysis. *BMJ*. 2020;:m3320. doi:10.1136/bmj.m3320
- 571 9 Metz TD, Clifton RG, Hughes BL, *et al*. Disease Severity and Perinatal Outcomes of  
572 Pregnant Patients With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol*  
573 2021;**137**:571–80.
- 574 10 Villar J, Ariff S, Gunier RB, *et al*. Maternal and Neonatal Morbidity and Mortality Among  
575 Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational  
576 Cohort Study. *JAMA Pediatr* Published Online First: 22 April 2021.  
577 doi:10.1001/jamapediatrics.2021.1050
- 578 11 Ellington S, Strid P, Tong VT, *et al*. Characteristics of Women of Reproductive Age with  
579 Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January  
580 22-June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:769–75.
- 581 12 Farrell R, Michie M, Pope R. Pregnant Women in Trials of Covid-19: A Critical Time to  
582 Consider Ethical Frameworks of Inclusion in Clinical Trials. *J Empir Res Hum Res Ethics*  
583 2020;**42**:17–23.
- 584 13 Sexual and Reproductive Health and Research. Definition and categorization of the timing  
585 of mother-to-child transmission of SARS-CoV-2.  
586 2021.[https://www.who.int/publications/i/item/WHO-2019-nCoV-mother-to-child-](https://www.who.int/publications/i/item/WHO-2019-nCoV-mother-to-child-transmission-2021.1)  
587 [transmission-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-mother-to-child-transmission-2021.1) (accessed 2 Sep 2021).
- 588 14 Kimberlin DW, Stagno S. Can SARS-CoV-2 Infection Be Acquired In Utero?: More  
589 Definitive Evidence Is Needed. *JAMA* 2020;**323**:1788–9.
- 590 15 Mahyuddin AP, Kanneganti A, Wong JLJ, *et al*. Mechanisms and evidence of vertical  
591 transmission of infections in pregnancy including SARS-CoV-2. *Prenat Diagn* Published  
592 Online First:

- 593 2020.[https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/pd.5765?casa\\_token=7xnIU0uz](https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/pd.5765?casa_token=7xnIU0uz)  
594 zAgAAAAA:IIIT283\_cYNKnvzUvkGQ0iMhbS9R0HJkLnu640BWid2pQGWPorHSyel\_VRhBx  
595 J1UaNt9LitF-PDUCPQ
- 596 16 Carosso A, Cosma S, Serafini P, *et al.* How to reduce the potential risk of vertical  
597 transmission of SARS-CoV-2 during vaginal delivery? *Eur J Obstet Gynecol Reprod Biol*  
598 2020;**250**:246–9.
- 599 17 Knight M, Bunch K, Vousden N, *et al.* Characteristics and outcomes of pregnant women  
600 admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based  
601 cohort study. *BMJ* 2020;**369**:m2107.
- 602 18 Liu W, Wang J, Li W, *et al.* Clinical characteristics of 19 neonates born to mothers with  
603 COVID-19. *Front Med* 2020;**14**:193–8.
- 604 19 Higgins JPT, Thomas J, Chandler J, *et al.* *Cochrane Handbook for Systematic Reviews of*  
605 *Interventions*. John Wiley & Sons 2019.
- 606 20 Maternal, Newborn, Child and Adolescent health, Ageing and COVID-19.  
607 <https://www.who.int/teams/maternal-newborn-child-adolescent-health-and-ageing/covid-19>  
608 (accessed 26 Jul 2021).
- 609 21 Tierney J, Vale CL, Burdett S, *et al.* Timely and reliable evaluation of the effects of  
610 interventions: a framework for adaptive meta-analysis (FAME). *Trials* 2017;**18**:132–3.
- 611 22 Yap M, Debenham L, Kew T, *et al.* Clinical manifestations, prevalence, risk factors,  
612 outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and  
613 postpartum: a living systematic review protocol. *BMJ Open* 2020;**10**:e041868.
- 614 23 Definitions C. WHO COVID-19: Case Definitions.
- 615 24 Papageorghiou AT, Ohuma EO, Altman DG, *et al.* International standards for fetal growth  
616 based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the  
617 INTERGROWTH-21st Project. *Lancet* 2014;**384**:869–79.
- 618 25 Villar J, Ismail LC, Victora CG, *et al.* International standards for newborn weight, length,  
619 and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of  
620 the INTERGROWTH-21st Project. *Lancet* 2014;**384**:857–68.
- 621 26 A prospective cohort study investigating maternal, pregnancy and neonatal outcomes for  
622 women and neonates infected with SARS-CoV-2. World Health Organization 2020.  
623 [https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-](https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2)  
624 [pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2](https://www.who.int/publications/m/item/a-prospective-cohort-study-investigating-maternal-pregnancy-and-neonatal-outcomes-for-women-and-neonates-infected-with-sars-cov-2)  
625 (accessed 26 Jul 2021).
- 626 27 CDC. Investigating the Impact of COVID-19 during Pregnancy.  
627 2021.[https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html)  
628 [populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/special-populations/pregnancy-data-on-covid-19/what-cdc-is-doing.html) (accessed 26 Jul 2021).
- 629 28 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;**7**:177–88.
- 630 29 Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses  
631 with binary outcomes. *Stat Med* 2008;**27**:746–63.

- 632 30 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*  
633 2002;**21**:1539–58.
- 634 31 Guyatt GH, Thorlund K, Oxman AD, *et al.* GRADE guidelines: 13. Preparing Summary of  
635 Findings tables and evidence profiles—continuous outcomes. *Journal of Clinical*  
636 *Epidemiology*. 2013;**66**:173–83. doi:10.1016/j.jclinepi.2012.08.001
- 637 32 Guyatt GH, Oxman AD, Kunz R, *et al.* GRADE guidelines 6. Rating the quality of  
638 evidence—imprecision. *J Clin Epidemiol* 2011;**64**:1283–93.
- 639 33 Seidler AL, Hunter KE, Cheyne S, *et al.* A guide to prospective meta-analysis. *BMJ*  
640 2019;**367**:l5342.
- 641 34 Smith ER, Flaherman VJ. Why you should share your data during a pandemic. *BMJ Glob*  
642 *Health* 2021;**6**. doi:10.1136/bmjgh-2021-004940
- 643 35 Petkova E, Antman EM, Troxel AB. Pooling Data From Individual Clinical Trials in the  
644 COVID-19 Era. *JAMA* 2020;**324**:543–5.

645

646

## 647 **Supporting information**

648 **S1 File. Data modules and core variables - version June 2, 2020**

649 **S2 File. Data modules and core variables - version November 8, 2020**

650 **S3 File. Description of participating studies and key stakeholders**

651

652

653

